Emerging Companies

GentiBio: combining trio of platforms to enhance Treg therapies

GentiBio launched this summer with a suite of technologies to develop next-generation Treg cell therapies that overcome several of the modality’s historical shortcomings, including stability and specificity. The company, which is focused on autoimmune, alloimmune...

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

Led by Bing Li and Debra Yu, Perceptive’s LianBio has launched with the goal of speeding the entrance of new medicines into Asian markets, leading with a registration-ready cardiomyopathy candidate from MyoKardia and a Phase...

T-knife: creating TCR factories with transgenic mice

Armed with a €66 million ($78.2 million) series A round, T-knife emerged from stealth Thursday with plans to bring four TCR therapies into clinical testing by 2022 using a transgenic mouse platform designed to generate...

Off-the-shelf cell therapy pioneers, Versant launch Matterhorn to tackle broad range of cancers

Versant’s Ridgeline incubator in Basel has launched Matterhorn with an off-the-shelf MR1T cell therapy designed to address a broader range of cancers than CAR T and TCR therapies. The company raised a $30 million series...

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

Nura Bio emerged from stealth last week with a $73 million series A and strategy to tackle neurological disorders based on two prevailing theories -- increasing neuroprotection and reducing neuroinflammation. Led by Vir and Biogen...

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with a camelid-derived antibody platform and its first to deploy the technology as a countermeasure against pandemic threats. ExeVir, which...

Bright Peak synthesizing proteins like they’re small molecules with $35M from Versant

Bright Peak thinks its medicinal chemistry approach to protein design will make its synthetic cytokines stand out from the pack. Built by Versant Ventures’ Basel-based Ridgeline outpost with technology licensed from ETH Zurich, Bright Peak...

Frazier, Marcadia founders reunite for rare endocrine diseases in MBX’s $34.6M A round

Kent Hawryluk and Richard DiMarchi are following up on the first two companies they formed together, diabetes-focused Marcadia and MB2, with rare endocrine diseases play MBX Biosciences. Frazier, which led Marcadia Biotech Inc.’s series A...

On track for 2021 launch, Seer unveils unbiased proteomics tech and latest $55M round

With a fresh $55 million and a new publication detailing its nanoparticle-based technology, Seer thinks it can bring the scale and speed of next-generation sequencing to proteomics next year. On Wednesday, Seer announced a series...

Elevation debuts with tumor-agnostic mAb in Phase II

Led by former Loxo Chairman Steve Elms, Elevation emerged from stealth Tuesday with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners. Elevation Oncology Inc. is developing therapies for cancers...

Deep Longevity: Insilico spinout clocks biological age

Insilico spinout Deep Longevity came out of stealth last week with 17 sets of biomarkers, dubbed aging clocks, designed to measure the rate of aging that could be applied to measure treatment efficacy in clinical...

Jnana goes after metabolism-mediating proteins, gains Roche as partner

Jnana is developing small molecules against a relatively untapped class of proteins -- solute carriers -- to modulate cell metabolism. On Tuesday, the biotech closed its first deal with a large biopharma, partnering with Roche...

Hybrid CDMO-gene therapy developer Forge launches with $40M

With $40 million from an investor group led by Chris Garabedian’s PXV fund, newly launched Forge Biologics is building a hybrid company that will offer CDMO services to gene therapy companies while also developing its...

Acepodia: linking antitumor antibodies to immune cells

Acepodia is using its antibody-cell conjugation platform to link tumor-targeting antibodies to the surface of cell therapies while avoiding genetic engineering. The platform, which has the potential for cost savings compared with CAR T therapy,...

Fountain Therapeutics: an AI-based platform to reverse cellular aging

Fountain is using an unbiased data-driven approach to identify compounds that reverse the biological process of aging, and in contrast to the traditional disease hypothesis-driven approach, the company is agnostic to indication. “Eighty percent of...